Home / Business and Economy / Pathos AI Powers Alzheimer's Drug Quest

Pathos AI Powers Alzheimer's Drug Quest

23 Oct

Summary

Pathos AI collaborates on AI tools for neurological disorders.
Bristol Myers Squibb leads a $237 million funding round.
Pathos AI's valuation reaches approximately $3 billion.

Pathos AI is advancing the development of artificial intelligence tools for neurological conditions, including Alzheimer's disease. The company recently announced a significant collaboration with pharmaceutical giant Bristol Myers Squibb and healthcare technology firm Tempus AI. This partnership aims to leverage AI to accelerate drug discovery and development in these critical areas.

In conjunction with this collaboration, Pathos AI successfully closed a Series E funding round, raising $237 million. The investment was spearheaded by Bristol Myers Squibb, with participation from existing investors. This funding boosts Pathos AI's valuation to approximately $3 billion, signaling strong market confidence in its innovative approach.

Disclaimer: This story has been auto-aggregated and auto-summarised by a computer program. This story has not been edited or created by the Feedzop team.